Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability

Esther Meijer*, Ron T. Gansevoort

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)289-293
Number of pages5
JournalKidney International
Volume98
Issue number2
DOIs
Publication statusPublished - Aug-2020

Keywords

  • TOLVAPTAN
  • MODEL

Cite this